EBS Q4 2020 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$446M

Q4 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$583M+73.4% YoY

Gross Profit

$356M61.0% margin

Operating Income

$258M44.3% margin

Net Income

$185M31.8% margin

EPS (Diluted)

$3.44

QoQ Revenue Growth

+51.3%

Cash Flow

Operating Cash Flow

$245M

Free Cash Flow

$209M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$2.9B

Total Liabilities

$1.4B

Stockholders' Equity

$1.4B

Cash & Equivalents

$621M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$583M	$336M	+73.4%
Gross Profit	$356M	$203M	+74.8%
Operating Income	$258M	$78M	+232.2%
Net Income	$185M	$47M	+295.3%

Revenue Segments

Product

$341M58%

Contract Development And Manufacturing

$199M34%

Contracts and Grants

$43M7%

Geographic Segments

UNITED STATES

$400M69%

Non-US

$183M31%